Advertisement
| embark study prostate cancer: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| embark study prostate cancer: The Virility Paradox Charles J. Ryan, MD, 2018-02-27 Testosterone makes us stronger, happier, and smarter. It also makes us meaner, more violent and more selfish. A scientific look into the vast and unexpected influence testosterone has on our behavior, our society, and our bodies. The brain of every man—and every woman—is shaped by this tiny molecule from before birth: it propels our drive for exploration and risk, for competition and creation, and even our survival. The effects of testosterone permeate the traditions, philosophy, and literature of every known culture—without it, the world would be a drastically different place. Testosterone also has a role in humanity's darker side, contributing to violence, hubris, poverty, crime, and selfishness. Recent revelations of the science of testosterone show that high levels will deplete compassion and generosity, and even reduce the affection we show our children. In The Virility Paradox, internationally renowned oncologist and prostate cancer researcher Charles Ryan explores this complex chemical system responsible for a diverse spectrum of human behaviors and health in both men and women. Ryan taps his vast experience treating prostate cancer with testosterone-lowering therapy, observing that this often leads to profound changes in the patients' perspectives on their lives and relationships. Often, for the better. Ryan uses the journeys of these patients and others to illustrate the vast and sometimes unexpected influence testosterone has on human lives. Through the stories of real men and women, he also explores the connections between testosterone and conditions like dementia, autism, and cancer, as well as the biological underpinnings of sexual assault and the effects it has on everything from crime to investing to everyday choices we make. Integrating the molecular and the medical, sociology and storytelling, The Virility Paradox;offers a fascinating look at how one hormone has shaped history, and the connections between our biology, our behavior, and our best selves. |
| embark study prostate cancer: Testing Treatments Imogen Evans, Hazel Thornton, Iain Chalmers, Paul Glasziou, 2011 This work provides a thought-provoking account of how medical treatments can be tested with unbiased or 'fair' trials and explains how patients can work with doctors to achieve this vital goal. It spans the gamut of therapy from mastectomy to thalidomide and explores a vast range of case studies. |
| embark study prostate cancer: Adenocarcinoma of the Prostate Andrew W. Bruce, John Trachtenberg, 2012-12-06 Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book. |
| embark study prostate cancer: Let Sleeping Dogs Lie? Simon Chapman, Alexandra Barratt, Martin Stockler, 2010 Few issues have been as divisive as prostate cancer screening. While some prominent Australian urologists are very active in talking up the importance of prostate cancer screening, few Australians would be aware that aside from some professional urological societies, no prevention agency currently recommends screening for the disease. |
| embark study prostate cancer: Active Surveillance for Localized Prostate Cancer Laurence Klotz, 2012-06-21 Active Surveillance for Localized Prostate Cancer: A New Paradigm for Clinical Management will serve as a useful resource for physicians dealing with, and interested in, this complex and evolving branch of prostate cancer management. The book will also be of interest to scientifically literate patients and their families. The volume provides an introduction to the concept of active surveillance in oncology in general and prostate cancer specifically. The primary focus is to provide a comprehensive guide to the management of patients on surveillance. The volume covers the many complexities and nuances to this approach including, patient selection, risk assessment, how to overcome 'cancer hysteria' when counseling patients, identifying appropriate triggers for intervention, use of PSA kinetics and MR imaging information, technique and frequency of biopsies, secondary prevention interventions, and the relative roles of surveillance and focal therapy. |
| embark study prostate cancer: Chemotherapy and Immunotherapy in Urologic Oncology Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, 2020-09-29 This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects. |
| embark study prostate cancer: Calcium Entry Channels in Non-Excitable Cells Juliusz Ashot Kozak, James W. Putney, Jr., 2017-07-14 Calcium Entry Channels in Non-Excitable Cells focuses on methods of investigating the structure and function of non-voltage gated calcium channels. Each chapter presents important discoveries in calcium entry pathways, specifically dealing with the molecular identification of store-operated calcium channels which were reviewed by earlier volumes in the Methods in Signal Transduction series. Crystallographic and pharmacological approaches to the study of calcium channels of epithelial cells are also discussed. Calcium ion is a messenger in most cell types. Whereas voltage gated calcium channels have been studied extensively, the non-voltage gated calcium entry channel genes have only been identified relatively recently. The book will fill this important niche. |
| embark study prostate cancer: Textbook of Clinical Trials David Machin, Simon Day, Sylvan Green, 2007-01-11 Now published in its Second Edition, the Textbook of Clinical Trials offers detailed coverage of trial methodology in diverse areas of medicine in a single comprehensive volume. Praise for the First Edition: ... very useful as an introduction to clinical research, or for those planning specific studies within therapeutic or disease areas. BRITISH JOURNAL OF SURGERY, Vol. 92, No. 2, February 2005 The book’s main concept is to describe the impact of clinical trials on the practice of medicine. It separates the information by therapeutic area because the impact of clinical trials, the problems encountered, and the numbers of trials in existence vary tremendously from specialty to specialty. The sections provide a background to the disease area and general clinical trial methodology before concentrating on particular problems experienced in that area. Specific examples are used throughout to address these issues. The Textbook of Clinical Trials, Second Edition: Highlights the various ways clinical trials have influenced the practice of medicine in many therapeutic areas Describes the challenges posed by those conducting clinical trials over a range of medical specialities and allied fields Additional therapeutic areas are included in this Second Edition to fill gaps in the First Edition as the number and complexity of trials increases in this rapidly developing area Newly covered or updated in the Second Edition: general surgery, plastic surgery, aesthetic surgery, palliative care, primary care, anaesthesia and pain, transfusion, wound healing, maternal and perinatal health, early termination, organ transplants, ophthalmology, epilepsy, infectious disease, neuro-oncology, adrenal, thyroid and urological cancers, as well as a chapter on the Cochrane network An invaluable resource for pharmaceutical companies, the Textbook of Clinical Trials, Second Edition appeals to those working in contract research organizations, medical departments and in the area of public health and health science alike. |
| embark study prostate cancer: Focal Therapy in Prostate Cancer Hashim Uddin Ahmed, Manit Arya, Peter R. Carroll, Mark Emberton, 2011-12-27 This book comprehensively reviews the potential of focal therapy and discusses why the changing face of prostate cancer warrants a change in the way we treat men with the disease. It deals with the mechanisms by which disease can be localized within the gland and then the different technologies used for focal ablation. Bringing together eminent contributors in one accessible reference, this book introduces focal therapy to all urologists, oncologists, and radiologists who are involved in the treatment of men with prostate cancer. |
| embark study prostate cancer: Scarcity Sendhil Mullainathan, Eldar Shafir, 2013-09-03 A surprising and intriguing examination of how scarcity—and our flawed responses to it—shapes our lives, our society, and our culture |
| embark study prostate cancer: The Scientific Basis of Urology Anthony R. Mundy, John Fitzpatrick, David E. Neal, Nicholas J. R. George, 1999-03-01 Every area, function, illness and cure of the urinary tract, along with specific discussions of the relevant anatomy and physiology, is covered in clearly written text, abundantly illustrated with full colour photographs and diagrams. |
| embark study prostate cancer: Molecular Biology of the Cell , 2002 |
| embark study prostate cancer: Bladder Cancer Ashish M. Kamat, Peter C. Black, 2021-07-24 This book provides a practical, comprehensive, state-of-the-art review of bladder cancer. A valuable resource for anyone with an interest in urothelial tumors, this text brings together a multidisciplinary team of experts who have distilled their vast years of experience and knowledge into a concise, easy to digest format. Topics covered range from importance of a pattern recognition in diagnosis and pathologic evaluation to ‘how I do it’ tips on patient selection for appropriate therapies such as chemotherapy, immunotherapy, surgery and radiation. Bridging the gap between a traditional textbook and hands-on experience, this book provides a practical guide to managing day-to-day issues and challenges and brings an algorithmic approach to avoid common pitfalls. Bladder Cancer: A Practical Guide provides a concise yet comprehensive summary of the current status of the field of bladder cancer treatment, guiding patient management and stimulating investigative efforts. |
| embark study prostate cancer: The Practical Guide , 2002 |
| embark study prostate cancer: The Emperor of All Maladies Siddhartha Mukherjee, 2011-08-09 Winner of the Pulitzer Prize and a documentary from Ken Burns on PBS, this New York Times bestseller is “an extraordinary achievement” (The New Yorker)—a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence. Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with—and perished from—for more than five thousand years. The story of cancer is a story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception. Mukherjee recounts centuries of discoveries, setbacks, victories, and deaths, told through the eyes of his predecessors and peers, training their wits against an infinitely resourceful adversary that, just three decades ago, was thought to be easily vanquished in an all-out “war against cancer.” The book reads like a literary thriller with cancer as the protagonist. Riveting, urgent, and surprising, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer. |
| embark study prostate cancer: Clinical Application of Urologic Catheters, Devices and Products Diane K. Newman, Eric S. Rovner, Alan J. Wein, 2017-12-09 Designed to provide a comprehensive and state-of-the-art overview of the use of urologic catheters and devices in clinical practice. Sections of the book have been structured to review the overall indication for the use of urologic catheters and devices, types available, complications and management. This text fills a critical need for resource materials on these topics. The book also includes highly practical presentations and of typical patients with catheters or devices seen in the clinical practice of geriatric urology, all in the form of case presentations with expert analysis and editorial commentary. Highlighting the integrated multidimensional aspects of care for urology patients, this book is unique in the inclusion of collaborating multidisciplinary authors who are all recognized experts in their field. Written entirely by urologic specialists, Clinical Application of Urologic Catheters, Devices and Products provides a unique and valuable resource in the field of practicing urology, for urologists, nurse practitioners, physician assistants, and for those currently in training. |
| embark study prostate cancer: Immunoepidemiology Peter J. Krause, Paula B. Kavathas, Nancy H. Ruddle, 2019-10-24 This textbook focuses on the nascent field of Immunoepidemiology that addresses how differences in immune responses among individuals affect the epidemiology of infectious diseases, cancer, hypersensitivity, and autoimmunity. The idea for the book originated from a course entitled “Immunology for Epidemiologists“ at the Yale School of Public Health. While many fine textbooks are available that address the immunological responses of individuals to pathogens, these provided very little information regarding how immunological variation among populations affects the epidemiology of disease. And yet, it has long been recognized that there is great immunologic diversity among people, which can have a profound effect on the epidemiology of disease. Careful review of the immunologic and epidemiologic literature revealed that there have been relatively few publications concerning immunoepidemiology and that no textbook is available on the subject. This textbook therefore aims to fill this void by providing a much-needed tool to comprehensively and efficiently teach immunoepidemiology. The book includes a section on the basic principles of immunology, and then applies them to particular examples of disease in human populations. The target audience for this text book are Masters of Public Health students. Others who should also find it of interest include PhD students in epidemiology, immunology, medical students, generalists, and specialists in immunology, infectious diseases, cancer, and rheumatology. |
| embark study prostate cancer: Diagnosis and Treatment of Genitourinary Malignancies Kenneth J. Pienta, 2012-12-06 The field of genito-urinary oncology is rapidly evolving at virtually every level. Significant advances have been made in our understanding of the molecular and cellular events which contribute to the generation of GU malignancies. At the same time, similar advances have been made in the clinical arena which have improved the diagnosis and treatment of urologic cancers. This volume attempts to summarize those advances which most impact us as clinicians, and has been divided into three sections. Section One, `Diagnostic advances: the use of molecular medicine in the diagnosis and prognosis of GU malignancies', details how epidemiologic studies and new molecular techniques are impacting our ability to diagnose and treat GU tumors. Section Two, `Surgical and radiation advances', details the recent major advances in the treatment of organ-confined cancers. Section Three, `Medical advances', addresses major issues in the treatment of metastatic disease. This volume will serve as a compendium of the advances, both at the basic science and clinical levels, which are currently impacting practicing oncologists and urologists. |
| embark study prostate cancer: Core Curriculum for Urologic Nursing Diane Newman, Jean Wyman, Valre Welch, 2016-11-01 This comprehensive publication is an excellent, unique, resource for all urologic nurses.This new practice resource contains over 700 pages of content written by and for urologic professionals. The high-quality content Impacts the everyday practice of RNs, APRNs, PAs, technicians, and urologic associates. Content encompasses every stage of life, from pediatric to geriatric patient populations. The Core offers fundamental curriculum for the novice and in-depth knowledge for the experienced practitioner in a hybrid text. The Core provides essential information and reflects the complexity, diversity, and unique clinical challenges encountered by urology nurses caring for the urologic patient across the lifespan. It provides a comprehensive resource for all urologic nurses and professionals, in all care settings, who are involved in the care of urologic patients, enabling them to practice confidently and delivery clinically effective, patient-centered care. |
| embark study prostate cancer: Urological Pathology Mahul B. Amin, John Eble, David Grignon, John Srigley, 2013-11-14 Knowledge in the field of urologic pathology is growing at an explosive pace. Today’s pathologists, specialists, and residents require a comprehensive and authoritative text that examines the full range of urological diseases and their diagnosis. Written by recognized leaders and educators in the field, the text provides readers with a detailed understanding of all diagnostic aspects of urological disease. Inside this unique resource, readers will explore a broad spectrum of practical information—including etiology, diagnostic criteria, molecular markers, differential diagnosis, ancillary tests, and clinical management. This is sure to be the new definitive text for urological pathology! |
| embark study prostate cancer: How to Read a Paper Trisha Greenhalgh, 2014-02-26 The best-selling introduction to evidence-based medicine In a clear and engaging style, How to Read a Paper demystifies evidence-based medicine and explains how to critically appraise published research and also put the findings into practice. An ideal introduction to evidence-based medicine, How to Read a Paper explains what to look for in different types of papers and how best to evaluate the literature and then implement the findings in an evidence-based, patient-centred way. Helpful checklist summaries of the key points in each chapter provide a useful framework for applying the principles of evidence-based medicine in everyday practice. This fifth edition has been fully updated with new examples and references to reflect recent developments and current practice. It also includes two new chapters on applying evidence-based medicine with patients and on the common criticisms of evidence-based medicine and responses. How to Read a Paper is a standard text for medical and nursing schools as well as a friendly guide for everyone wanting to teach or learn the basics of evidence-based medicine. |
| embark study prostate cancer: Handbook of EHealth Evaluation Francis Yin Yee Lau, Craig Kuziemsky, 2016-11 To order please visit https://onlineacademiccommunity.uvic.ca/press/books/ordering/ |
| embark study prostate cancer: Risk and Reason in Clinical Diagnosis Cym Anthony Ryle, 2019-06-13 Accurate diagnosis is the foundation of medical practice, but at the start of the diagnostic process, uncertainty is inevitable. The clinician's skills and cognitive attributes determine the quality of the initial differential diagnosis and thus the crucial first phases of investigation and treatment; mistakes are often self-propagating. Diagnostic error is a major cause of avoidable morbidity and mortality, and is the commonest reason for successful litigation. Risk and Reasoning in Clinical Diagnosis is an accessible and readable look at the diagnostic process. Dr. Cym Ryle presents the insights and concepts developed in cognitive psychology which have led to the consensus that in all domains human reasoning is primarily driven by unconscious, intuitive mechanisms; the contribution of structured, analytical thinking is variable and inconsistent. He notes that the risk of error is inseparable from these mechanisms. Dr. Ryle then develops a description of the diagnostic process which encompasses its form, strengths and fallibility, and illustrates this description with examples from his work as a general practitioner. He argues that improving diagnostic accuracy should be a priority, and that there is sufficient evidence to guide changes in medical training, in clinical practice, and in the culture and organisation of our institutions. He identifies specific, practical steps that can be taken by individual clinicians and by clinical teams, suggests priorities for action in our institutions, and considers the obstacles to progress. |
| embark study prostate cancer: When Breath Becomes Air (Indonesian Edition) Paul Kalanithi, 2016-10-06 Pada usia ketiga puluh enam, Paul Kalanithi merasa suratan nasibnya berjalan dengan begitu sempurna. Paul hampir saja menyelesaikan masa pelatihan luar biasa panjangnya sebagai ahli bedah saraf selama sepuluh tahun. Beberapa rumah sakit dan universitas ternama telah menawari posisi penting yang diimpikannya selama ini. Penghargaan nasional pun telah diraihnya. Dan kini, Paul hendak kembali menata ikatan pernikahannya yang merenggang, memenuhi peran sebagai sosok suami yang ia janjikan. Akan tetapi, secara tiba-tiba, kanker mencengkeram paru-parunya, melumpuhkan organ-organ penting dalam tubuhnya. Seluruh masa depan yang direncanakan Paul seketika menguap. Pada satu hari ia adalah seorang dokter yang menangani orang-orang yang sekarat, tetapi pada hari berikutnya, ia adalah pasien yang mencoba bertahan hidup. Apa yang membuat hidup berharga dan bermakna, mengingat semua akan sirna pada akhirnya? Apa yang Anda lakukan saat masa depan tak lagi menuntun pada cita-cita yang diidamkan, melainkan pada masa kini yang tanpa akhir? Apa artinya memiliki anak, merawat kehidupan baru saat kehidupan lain meredup? When Breath Becomes Air akan membawa kita bergelut pada pertanyaan-pertanyaan penting tentang hidup dan seberapa layak kita diberi pilihan untuk menjalani kehidupan. [Mizan, Bentang Pustaka, Memoar, Biografi, Kisah, Medis, Terjemahan, Indonesia] |
| embark study prostate cancer: Medical Apartheid Harriet A. Washington, 2008-01-08 NATIONAL BOOK CRITICS CIRCLE AWARD WINNER • The first full history of Black America’s shocking mistreatment as unwilling and unwitting experimental subjects at the hands of the medical establishment. No one concerned with issues of public health and racial justice can afford not to read this masterful book. [Washington] has unearthed a shocking amount of information and shaped it into a riveting, carefully documented book. —New York Times From the era of slavery to the present day, starting with the earliest encounters between Black Americans and Western medical researchers and the racist pseudoscience that resulted, Medical Apartheid details the ways both slaves and freedmen were used in hospitals for experiments conducted without their knowledge—a tradition that continues today within some black populations. It reveals how Blacks have historically been prey to grave-robbing as well as unauthorized autopsies and dissections. Moving into the twentieth century, it shows how the pseudoscience of eugenics and social Darwinism was used to justify experimental exploitation and shoddy medical treatment of Blacks. Shocking new details about the government’s notorious Tuskegee experiment are revealed, as are similar, less-well-known medical atrocities conducted by the government, the armed forces, prisons, and private institutions. The product of years of prodigious research into medical journals and experimental reports long undisturbed, Medical Apartheid reveals the hidden underbelly of scientific research and makes possible, for the first time, an understanding of the roots of the African American health deficit. At last, it provides the fullest possible context for comprehending the behavioral fallout that has caused Black Americans to view researchers—and indeed the whole medical establishment—with such deep distrust. |
| embark study prostate cancer: Disease Control Priorities, Third Edition (Volume 8) Donald A. P. Bundy, Nilanthi de Silva, Susan Horton, Dean T. Jamison, 2017-11-20 More children born today will survive to adulthood than at any time in history. It is now time to emphasize health and development in middle childhood and adolescence--developmental phases that are critical to health in adulthood and the next generation. Child and Adolescent Health and Development explores the benefits that accrue from sustained and targeted interventions across the first two decades of life. The volume outlines the investment case for effective, costed, and scalable interventions for low-resource settings, emphasizing the cross-sectoral role of education. This evidence base can guide policy makers in prioritizing actions to promote survival, health, cognition, and physical growth throughout childhood and adolescence. |
| embark study prostate cancer: Counterclockwise Ellen J. Langer, 2009 Scientifically riveting and practically empowering, Counterclockwise offers a bold new way to think about aging and lifelong health from the trailblazing social psychologist and author of the bestselling classic Mindfulness. |
| embark study prostate cancer: Prostate Cancer Survivorship Sanchia S. Goonewardene, Raj Persad, 2018-12-21 This book provides information on a range of issues related to prostate cancer survivorship, including; psychosexual care, health related quality of life, treatment, follow-up care, new psychosexual pathways, and acute and chronic co-morbidities. The book also covers the needs and challenges in survivorship care, the requirements of care, the future of survivorship care, and role of patient conferences. This book aims to give oncologists, urologists, and specialist nurses help in how to manage patients in the prostate cancer survivorship phase. This guidance is based on real life experiences handling prostate cancer survivorship, and is developed further through utilising the views of both health care professionals and patients. |
| embark study prostate cancer: Prostate Cancer: New Insights for the Healthcare Professional: 2012 Edition , 2012-12-10 Prostate Cancer: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Prostate Cancer. The editors have built Prostate Cancer: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Prostate Cancer in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Prostate Cancer: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| embark study prostate cancer: Accuracy Requirements and Uncertainties in Radiotherapy International Atomic Energy Agency, 2017-04-12 Accuracy requirements in radiation oncology have been defined in multiple publications; however, these have been based on differing radiation technologies. In the meantime, the uncertainties in radiation dosimetry reference standards have been reduced and more detailed patient outcome data are available. No comprehensive literature on accuracy and uncertainties in radiotherapy has been published so far. The IAEA has therefore developed a new international consensus document on accuracy requirements and uncertainties in radiation therapy, to promote safer and more effective patient treatments. This publication addresses accuracy and uncertainty issues related to the vast majority of radiotherapy departments including both external beam radiotherapy and brachytherapy. It covers clinical, radiobiological, dosimetric, technical and physical aspects. |
| embark study prostate cancer: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (U.S.), 1998 Of evidence-based recommendations -- Introduction -- Overweight and obesity: background -- Examination of randomized controlled trial evidence -- Treatment guidelines -- Summary of recommendations -- Future research. |
| embark study prostate cancer: Endourology Culley C. Carson, N. Reed Dunnick, 1985 |
| embark study prostate cancer: Gaseous Molecular Ions Eugen Illenberger, Jacques Momigny, 1992-05-26 Most of the matter in our solar system, and, probably, within the whole universe, exists in the form of ionized particles. On the other hand, in our natural environ ment, gaseous matter generally consists of neutral atoms and molecules. Only under certain conditions, such as within the path oflightning or in several technical devices (e. g. gas discharges, rocket engines, etc. ) will some of the atoms and molecules be ionized. It is also believed that the chemistry of the earth's troposphere predomi nantly proceeds via reactions between neutral particles. (The complex system of atmospheric chemistry will be treated in one of the forthcoming volumes to this series. ) Why, then, are ions considered so important that hundreds oflaboratories all over the world (including some of the most prestigious) are involved in research pro grams on ions, covering many different facets, from biochemistry to physics? One may obtain as many different answers as there are research groups busy in this field. There is, however, one simple, common feature which makes it attractive to work with ions: since they carry one or more net elementary charges, they can easily be gui ded, focused or separated by appropriate electric and magnetic fields, and, last but not least, they can easily be detected. Apart from these advantages, which are welcome and appreciated by the researcher, the study of molecular ions can provide insight into very fundamental aspects of the general behavior of molecules. |
| embark study prostate cancer: Animal Care and Use Committees John Timothy Allen, 1992 |
| embark study prostate cancer: Human Genetics and Genomics Bruce R. Korf, Mira B. Irons, 2012-11-19 This fourth edition of the best-selling textbook, Human Genetics and Genomics, clearly explains the key principles needed by medical and health sciences students, from the basis of molecular genetics, to clinical applications used in the treatment of both rare and common conditions. A newly expanded Part 1, Basic Principles of Human Genetics, focuses on introducing the reader to key concepts such as Mendelian principles, DNA replication and gene expression. Part 2, Genetics and Genomics in Medical Practice, uses case scenarios to help you engage with current genetic practice. Now featuring full-color diagrams, Human Genetics and Genomics has been rigorously updated to reflect today’s genetics teaching, and includes updated discussion of genetic risk assessment, “single gene” disorders and therapeutics. Key learning features include: Clinical snapshots to help relate science to practice 'Hot topics' boxes that focus on the latest developments in testing, assessment and treatment 'Ethical issues' boxes to prompt further thought and discussion on the implications of genetic developments 'Sources of information' boxes to assist with the practicalities of clinical research and information provision Self-assessment review questions in each chapter Accompanied by the Wiley E-Text digital edition (included in the price of the book), Human Genetics and Genomics is also fully supported by a suite of online resources at www.korfgenetics.com, including: Factsheets on 100 genetic disorders, ideal for study and exam preparation Interactive Multiple Choice Questions (MCQs) with feedback on all answers Links to online resources for further study Figures from the book available as PowerPoint slides, ideal for teaching purposes The perfect companion to the genetics component of both problem-based learning and integrated medical courses, Human Genetics and Genomics presents the ideal balance between the bio-molecular basis of genetics and clinical cases, and provides an invaluable overview for anyone wishing to engage with this fast-moving discipline. |
| embark study prostate cancer: Drug Design Arli Aditya Parikesit, 2021-06-16 Right before the COVID-19 pandemic declared by the World Health Organization (WHO), life sciences have incited novel areas of studies that revolutionize the health sector. They are the studies of structural bioinformatics, pharmacogenomics, and metabolomics. The structural bioinformatics field is the very foundation of drug design research, as it provides insight into the molecular simulations and interactions between the biomolecules and the drug candidates. Secondly, pharmacogenomics is the starting point of any efforts in developing personalized medicine. Lastly, metabolomics provides instrumentation to elicit biomarkers for various diseases and health conditions. These studies have enabled current accelerated effort in COVID-19 research, as well as other communicable and non-communicable diseases. |
| embark study prostate cancer: Prostate Cancer Adam P. Dicker, Adam P. Dicker, MD, PhD, William Kevin Kelly, DO, Nicholas G. Zaorsky, MD, Edouard J. Trabulsi, MD, Charles R Thomas, 2014-12-17 This book admirably covers prostate cancer. It is written in an easily digestible manner for non-experts and emphasizes the importance of a team approach to treatment of patients with this disease.--Doody's Reviews With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice. The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life. A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study. Key Features: Delineates a practical, concise approach to multidisciplinary management of prostate cancer Provides a wide range of perspectives and expertise Written and edited by an international, multidisciplinary team of prostate cancer specialists Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data |
| embark study prostate cancer: The Underactive Bladder Michael B. Chancellor, Ananias C. Diokno, 2015-11-24 This book provides up-to-date guidance on optimal care of the patient with an underactive bladder. It covers all aspects of management, including clinical evaluation, urodynamic diagnosis, standard care, drug therapy, and emerging treatment options. Nursing issues are extensively discussed, and advice offered on the use of catheters and avoidance of catheter-related complications. Further chapters address epidemiology, pathophysiology, animal modeling, and health care costs. While most practitioners are familiar with overactive bladder, the converse condition of underactive bladder has generally remained far below the radar. As a consequence, there is still a lack of empirically validated treatments and effective treatment strategies. This is a matter of concern, especially as the burden of the condition is expected to rise in line with the aging of global populations. The Underactive Bladder is a major step forward in raising awareness, exploring best practices in patient care, and searching for future therapies. It will be invaluable for urologists, geriatricians, other specialists, researchers, and nurses. |
| embark study prostate cancer: CURRENT Medical Diagnosis and Treatment 2025 Maxine A. Papadakis, Michael W. Rabow, Kenneth R. McQuaid, Monica Gandhi, 2024-09-06 The #1 annual guide in adult internal medicine Each year CURRENT Medical Diagnosis and Treatment (CMDT) undergoes extensive revision to deliver new clinical developments in every field of adult internal medicine—making it the most popular annual textbook of its kind. For more than six decades, CMDT has been disseminating authoritative information that students, residents, and clinicians need to build their medical knowledge, expertise, and confidence. Written by top experts in their fields, chapters are formatted so you can find the most relevant diagnostic tools for day-to-day practice. CURRENT Medical Diagnosis & Treatment 2025 provides: Emphasis on the practical aspects of clinical diagnosis and disease management Coverage of more than 1,000 diseases and disorders Hundreds of quick-access drug treatment tables with indexed trade names Essentials of Diagnosis provides snapshot of common diseases/disorders Diagnostic and treatment algorithms and tables present critical information at a glance Carefully curated references provide peer-reviewed, evidence-based information and PMID numbers for quick online access Hundreds of full-color photographs and illustrations CMDT 2025 updates include: “Year in Review” table highlights nearly 100 recent advances impacting clinical practice New chapter on Substance Use Disorders New photos reflecting clinical conditions in a variety of skin tones Key updates to Viral & Rickettsial Infections chapter including concise directives on COVID-19 and measles Expanded coverage of major GI Disorders such as Crohn disease and ulcerative colitis |
A PHASE 3, RANDOMIZED, EFFICACY AND SAFETY STUDY OF …
Jun 2, 2023 · protocol (embark) statistical analysis plan pfizer confidential page 1 a phase 3, randomized, efficacy and safety study of enzalutamide in combination with leuprolide, …
Outcomes of men with high-risk biochemically recurrent …
Methods: EMBARK is a double-blind phase 3 study of pts with high- risk BCR (i.e., PSA doubling time (PSADT) #9 months and PSA $2 ng/mL above nadir post- radiotherapy [RT] or $1 ng/mL …
e new england journal o medicine
In this phase 3 trial, we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less.
Metastasis-Free Survival Versus Treatment-Free Survival in ...
May 16, 2024 · FIG 1. Hypothetical comparison of a surveillance strategy for biochemically recurrent prostate cancer to the EMBARK strategy with enzalutamide monotherapy. Black …
abstracts - Annals of Oncology
3 EMBARK (NCT02319837) trial. Pt-reported outcomes (PROs) provide a pt perspec-tive on disease/treatment (Tx) experience not captured by clinical assessment. Methods: nmHSPC pts …
Press Release - Astellas Pharma
Mar 25, 2024 · Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence" issued on September 12, 2023. About EMBARK The Astellas- and Pfizer-led …
Secondary outcomes by prior definitive treatment (tx) in …
Background: In the phase 3 EMBARK trial, combo vs leuprolide alone meaningfully improved metastasis-free survival (primary endpoint) and secondary efficacy endpoints. Secondary …
Enzalutamide in biochemically recurrent prostate cancer: key …
EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen depriva-tion therapy alone, in …
Outcomes of men with high-risk biochemically recurrent …
Methods: EMBARK is a double-blind phase 3 study of pts with high-risk BCR (i.e., PSA doubling time (PSADT) #9 months and PSA $2 ng/mL above nadir post-radiotherapy [RT] or $1 ng/mL …
Phase 3 Study Shows XTANDI® (enzalutamide) plus …
Mar 17, 2023 · Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK …
Enzalutamide in Men With High-Risk Biochemically Recurrent …
sensitive prostate cancer (PC) with biochemical recurrence (BCR) at high risk for metastasis. This approval was granted based on data from the global, phase 3 EMBARK study (NCT02319837) …
Improved Outcomes with Enzalutamide in Biochemically …
EMBARK ist eine dreiarmige Phase-3-Studie, die die Kombination aus Enzalutamid (160mg tgl.) plus Leuprorelin alle 12 Wochen, Placebo plus Leuprorelin oder Enzalutamid-Monotherapie, …
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of …
May 8, 2023 · “The EMBARK study is a Phase 3 trial exploring the potential of enzalutamide in patients with non-metastatic hormone-sensitive prostate cancer with high-risk BCR,” said …
LBA02-10 LBA02-09 - auajournals.org
METHODS: EMBARK is a randomized, phase 3 study of pts with BCR considered high-risk: PSA doubling time 9 months and PSA 2 ng/mL above nadir post-radiotherapy (RT) or 1 ng/mL after …
Incidence of EMBARK and EAU high-risk biochemical …
Incidence of EMBARK and EAU high-risk biochemical recurrence and prostate cancer mortality: A real-life population-based study. Background: The EMBARK trial proved the efficacy of …
High-risk biochemical recurrence of locally treated prostate …
EMBARK has randomized 1068 patients with a high-risk BCR to androgen deprivation therapy (ADT) alone, ADT enzalutamide, or enzalutamide alone. At five years, the metastasis-free …
A phase 3 randomised study of enzalutamide plus leuprolide …
EMBARK is the first study designed to determine whether early, combined therapy with enzalutamide plus a luteinising hormone-releasing hormone agonist (LHRHa) or enzalutamide …
Press Release - Astellas Pharma
Sep 13, 2023 · The EMBARK study met its primary endpoint of metastasis-free survival (MFS) for the XTANDI plus leuprolide arm, demonstrating a statistically significant reduction in the risk of …
Editorials Delaying Prostate-Specific Antigen Progression in ...
Jan 23, 2024 · Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful? Treating prostate cancer with intensified androgen …
PSMA PET findings in an EMBARK-like cohort of patients with …
Background: The EMBARK trial is a phase 3, randomized, study evaluating use of enzalutamide with or without concomitant leuprolide in non-metastatic castrate sensitive prostate cancer …
A PHASE 3, RANDOMIZED, EFFICACY AND SAFETY STUDY OF …
Jun 2, 2023 · protocol (embark) statistical analysis plan pfizer confidential page 1 a phase 3, randomized, efficacy and safety study of enzalutamide in combination with leuprolide, …
Outcomes of men with high-risk biochemically recurrent …
Methods: EMBARK is a double-blind phase 3 study of pts with high- risk BCR (i.e., PSA doubling time (PSADT) #9 months and PSA $2 ng/mL above nadir post- radiotherapy [RT] or $1 ng/mL …
e new england journal o medicine
In this phase 3 trial, we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less.
Metastasis-Free Survival Versus Treatment-Free Survival in ...
May 16, 2024 · FIG 1. Hypothetical comparison of a surveillance strategy for biochemically recurrent prostate cancer to the EMBARK strategy with enzalutamide monotherapy. Black …
abstracts - Annals of Oncology
3 EMBARK (NCT02319837) trial. Pt-reported outcomes (PROs) provide a pt perspec-tive on disease/treatment (Tx) experience not captured by clinical assessment. Methods: nmHSPC …
Press Release - Astellas Pharma
Mar 25, 2024 · Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence" issued on September 12, 2023. About EMBARK The Astellas- and Pfizer-led …
Secondary outcomes by prior definitive treatment (tx) in …
Background: In the phase 3 EMBARK trial, combo vs leuprolide alone meaningfully improved metastasis-free survival (primary endpoint) and secondary efficacy endpoints. Secondary …
Enzalutamide in biochemically recurrent prostate cancer: key …
EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen depriva-tion therapy alone, in …
Outcomes of men with high-risk biochemically recurrent …
Methods: EMBARK is a double-blind phase 3 study of pts with high-risk BCR (i.e., PSA doubling time (PSADT) #9 months and PSA $2 ng/mL above nadir post-radiotherapy [RT] or $1 ng/mL …
Phase 3 Study Shows XTANDI® (enzalutamide) plus …
Mar 17, 2023 · Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK …
Enzalutamide in Men With High-Risk Biochemically Recurrent …
sensitive prostate cancer (PC) with biochemical recurrence (BCR) at high risk for metastasis. This approval was granted based on data from the global, phase 3 EMBARK study (NCT02319837) …
Improved Outcomes with Enzalutamide in Biochemically …
EMBARK ist eine dreiarmige Phase-3-Studie, die die Kombination aus Enzalutamid (160mg tgl.) plus Leuprorelin alle 12 Wochen, Placebo plus Leuprorelin oder Enzalutamid-Monotherapie, …
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of …
May 8, 2023 · “The EMBARK study is a Phase 3 trial exploring the potential of enzalutamide in patients with non-metastatic hormone-sensitive prostate cancer with high-risk BCR,” said …
LBA02-10 LBA02-09 - auajournals.org
METHODS: EMBARK is a randomized, phase 3 study of pts with BCR considered high-risk: PSA doubling time 9 months and PSA 2 ng/mL above nadir post-radiotherapy (RT) or 1 ng/mL after …
Incidence of EMBARK and EAU high-risk biochemical …
Incidence of EMBARK and EAU high-risk biochemical recurrence and prostate cancer mortality: A real-life population-based study. Background: The EMBARK trial proved the efficacy of …
High-risk biochemical recurrence of locally treated prostate …
EMBARK has randomized 1068 patients with a high-risk BCR to androgen deprivation therapy (ADT) alone, ADT enzalutamide, or enzalutamide alone. At five years, the metastasis-free …
A phase 3 randomised study of enzalutamide plus leuprolide …
EMBARK is the first study designed to determine whether early, combined therapy with enzalutamide plus a luteinising hormone-releasing hormone agonist (LHRHa) or enzalutamide …
Press Release - Astellas Pharma
Sep 13, 2023 · The EMBARK study met its primary endpoint of metastasis-free survival (MFS) for the XTANDI plus leuprolide arm, demonstrating a statistically significant reduction in the risk of …
Editorials Delaying Prostate-Specific Antigen Progression in ...
Jan 23, 2024 · Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful? Treating prostate cancer with intensified androgen …
PSMA PET findings in an EMBARK-like cohort of patients with …
Background: The EMBARK trial is a phase 3, randomized, study evaluating use of enzalutamide with or without concomitant leuprolide in non-metastatic castrate sensitive prostate cancer …
